Particularly for patients with MCL with high-risk disease profiles, including those with blastoid variants, elevated Ki-67 proliferation indices, TP53 gene mutations or increased protein expression, and disease progression within 24 months of initial diagnosis, the prognosis is generally poor (3). The gene discussed is MKI67; the disease is mantle cell lymphoma.